Teva Pharmaceuticals to Pay $450 Million in Settlement Over Kickback Allegations

Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. have agreed to pay $450 million to resolve allegations of kickback schemes and price fixing. The settlement, announced Thursday by the U.S. Department of Justice, addresses violations of the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), marking a major victory in the government's ongoing efforts to combat healthcare fraud.

The New Jersey-based Teva, the largest generic drug manufacturer in the United States, faced two distinct sets of allegations. The first stemmed from a 2020 complaint filed in the District of Massachusetts, accusing Teva of manipulating Medicare patients' copayments for Copaxone, a multiple sclerosis drug, from 2006 to 2017. During this period, Teva allegedly raised the drug's price while simultaneously coordinating with third parties to cover patients' out-of-pocket costs.

According to the Justice Department, Teva orchestrated a complex scheme involving a specialty pharmacy and two purportedly independent copay assistance foundations. These entities allegedly channeled Teva's donations specifically towards covering Medicare Copaxone patients' copays, a practice prohibited by the AKS. This manipulation allowed Teva to maintain high prices for Copaxone while shielding patients from the financial impact, effectively circumventing Medicare's copay structure designed to prevent artificial price inflation.

The second part of the settlement addresses allegations of price fixing. Teva USA was accused of conspiring with other generic drug manufacturers to fix prices for several drugs, including pravastatin (used to treat high cholesterol), clotrimazole, and tobramycin. This civil settlement follows a previous deferred prosecution agreement with the Justice Department's Antitrust Division, in which Teva USA paid a $225 million criminal penalty and admitted to price-fixing conspiracies with three other generic drug companies.

Principal Deputy Assistant Attorney General Brian M. Boynton emphasized the Justice Department's commitment to combating such practices, stating that kickback violations "distort physician and patient decision-making, thwart competition and bypass controls put in place to protect federal health care programs." His comments underscore the government's view that these schemes not only violate the law but also undermine the integrity of the healthcare system.

The Teva settlement is part of a larger government initiative to address fraud in the pharmaceutical industry. Since 2017, the U.S. has collected over $1 billion from pharmaceutical companies alleged to have used third-party foundations for unlawful copay coverage. The agreement with Teva represents the largest such settlement to date, highlighting the scale of the issue and the government's determination to address it.

Acting U.S. Attorney Joshua S. Levy for the District of Massachusetts, whose office has played a leading role in these cases, noted that their actions have "returned more than $1 billion to the Medicare system." This substantial recovery underscores the financial impact of these fraudulent practices on federal healthcare programs and, by extension, on taxpayers.

The resolution of the price-fixing allegations marks the seventh settlement related to generic drug price fixing, with total recoveries now exceeding $500 million. This pattern of settlements reveals a troubling trend in the generic drug industry and suggests that the practice may have been more widespread than previously understood.

The Teva case serves as a reminder of the legal and financial risks associated with attempts to manipulate the healthcare market. As regulatory scrutiny intensifies, pharmaceutical companies face increasing pressure to ensure compliance with federal laws governing drug pricing and marketing practices. The settlement sends a clear message to the industry about the potential consequences of engaging in kickback schemes or price-fixing conspiracies.

This case also highlights the ongoing challenges in maintaining ethical practices within the pharmaceutical sector. As the government continues its efforts to control drug costs and protect the integrity of federal healthcare programs, companies in the industry will need to navigate an increasingly complex regulatory landscape.

The $450 million settlement with Teva Pharmaceuticals represents a significant milestone in the government's fight against healthcare fraud. It underscores the Department of Justice's commitment to safeguarding the interests of taxpayers and beneficiaries of federal healthcare programs. As the pharmaceutical industry grapples with the implications of this and similar cases, it's clear that compliance and ethical business practices will be more critical than ever in shaping the future of healthcare in the United States.

The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.